Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albumin and Midodrine vs Midodrine for Recurrent Ascites in Decompensated Cirrhosis
NCT06245590Unknown
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- Feb 2024
- Primary completion
- Jan 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial in decompensated cirrhosis and ascites comparing Albumin + Midodrine with Midodrine + Standard of Care (2 arms). Primary endpoint: Survival free of transplant and TIPS at 6 months. Status: unknown.
02
Drugs
albumin (human)
03
Conditions
decompensated cirrhosisascites
Beyond the preview
Go deeper on NCT06245590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06245590.